Nicholas Hoffman & Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nicholas Hoffman & Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,000	Closed	-$397K	–	274
2022 Q3	$397K	Hold	5,000	–	–	0.02%	180
2022 Q2	$371K	Buy	+5,000	New	+$375K	0.02%	185

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Nicholas Hoffman & Company's XBI Position: Q4 2022 in Review

Nicholas Hoffman & Company sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 5,000 shares — an estimated $397K sold.

Nicholas Hoffman & Company first reported a position in XBI in Q2 2022 and held it in 2 quarters. The position peaked at $397K in Q3 2022. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Nicholas Hoffman & Company reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
Nicholas Hoffman & Company sold 5,000 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $397K.
Nicholas Hoffman & Company first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 2 quarters.
Nicholas Hoffman & Company's State Street SPDR S&P Biotech ETF position peaked at $397K in Q3 2022.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Nicholas Hoffman & Company's 13F filing for Q4 2022, filed 13 Feb 2023.